SGLT2 inhibition for patients with ADPKD - closing the evidence gap.

This study, again, found a highly significant benefit of empagliflozin regarding the primary endpoint, a composite of progression of kidney disease or death from cardiovascular causes (hazard ratio 0.72, 95% CI, 0.64 to 0.82).

also in 132,142 other papers